Pharma Stock Plummets on Skin Disease Trial

Jefferies called the data "painfully disappointing"

Deputy Editor
Sep 12, 2023 at 10:57 AM
facebook X logo linkedin

Publicly traded since May, Acelyrin Inc (NASDAQ:SLRN) stock is plummeting to record lows today. The shares are down 62% at $10.60 at last glance, after the pharma company's skin disease drug failed in a mid-to-late-stage trial. Jefferies slashed its price target to $15 from $31 after the event, with the analyst in coverage calling the data "painfully disappointing."

SLRN isn't typically too popular amongst options traders, though today's minor uptick in options activity represents five times the intraday average volume. The September 15 call is the most active contract, with new positions being bought to open there. Acelyrin stock has also landed on the short sell restricted (SSR) list today amid the volatility. 

All five of the analysts in coverage carry a "strong buy" rating on SLRN, leaving plenty of room for more bear notes. Plus, the 12-month consensus price target of $38 is now a 245.5% premium to current levels.

Prior to today's massive bear gap, SLRN had carved out a channel of higher highs during its first summer of trading, nearly hitting $30 in late August, with support at its ascending 40-day moving average. 



How to collect 1 dividend check every day for LIFE

Did you know you could collect 1 dividend check every day the market is open? You could also do it starting with just $605! For me, I'm collecting 70 dividend checks every quarter…which averages around 1.1 dividend checks every business day. There's no trading behind this... no penny stocks or high-risk investments. All you do is buy and hold and you're set. There's no set up required either. If you start buying the dividend stocks I show you today... you could collect 1 dividend per day starting as early as this week. Click here for all the details.